Akèy › Leksemi mieloïd egi › Illinois

Etid klinik pou Leksemi mieloïd egi nan Illinois

31 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan Illinois.

Vil nan Illinois

Tèks ofisyèl etid la (Anglè)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
Illinois CancerCare-Carthage, Carthage
ak 15 plis

Ap rekriteFaz 2

Laj 60 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

OSF Saint Anthony's Health Center, Alton
Rush-Copley Medical Center, Aurora
Advocate Outpatient Center - Aurora, Aurora
ak 54 plis

Ap rekriteEtid obsèvasyonVolontè an sante akeyi

Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

University of Chicago Comprehensive Cancer Center, Chicago

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Centralia Oncology Clinic, Centralia
Northwestern University, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
ak 13 plis

Ap rekriteFaz 2

Laj 18 a 59 · Tout sèks · Mizajou Sep 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

University of Chicago Medicine, Chicago
Illinois Cancer Specialists, Niles

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Advocate Outpatient Center - Aurora, Aurora
Advocate Good Shepherd Hospital, Barrington
OSF Saint Joseph Medical Center, Bloomington
ak 54 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Lurie Children's Hospital-Chicago, Chicago

Ap rekriteFaz 1

Jiska laj 21 · Tout sèks · Mizajou Sep 23, 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Northwestern University, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
ak 26 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Northwestern University, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
ak 14 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

OSF Saint Joseph Medical Center, Bloomington
Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
ak 29 plis

Ap rekriteFaz 2

Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Lurie Children's Hospital-Chicago, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
ak 5 plis

Ap rekriteFaz 3

6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

The University of Chicago Medical Center, Chicago

Ap rekriteFaz 1/2

30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

University of Chicago, Chicago

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Lurie Children's Hospital-Chicago, Chicago

Ap rekriteFaz 3

Laj 1 a 25 · Tout sèks · Mizajou Sep 4, 2026 · NCT07022678

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

City of Hope - Chicago, Zion

Ap rekriteFaz 1/2

Laj 12 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT04588922

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

US-Chigago IL-UHCHICAGO, Chicago

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

University of Chicago Comprehensive Cancer Center, Chicago

Ap rekriteFaz 1

Laj 18 a 75 · Tout sèks · Mizajou Aug 25, 2026 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Lurie Children's Hospital-Chicago, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
ak 6 plis

Ap rekriteFaz 1/2

Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Comer Children's Hospital, Chicago

Ap rekriteFaz 3

29 Days – 21 Years · Tout sèks · Mizajou Aug 24, 2026 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Loyola University Medical Center, Maywood

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Research Site, Decatur

Ap rekriteFaz 1/2

Laj 16 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT07155226

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Northwestern Memorial Hospital, Chicago
Rush University Medical Center, Chicago
University of Illinois at Chicago, Chicago
ak 3 plis

Ap rekriteEtid obsèvasyon

Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

University of Illinois Cancer Center, Chicago

Ap rekriteFaz 2

Laj 18 a 65 · Tout sèks · Mizajou Jun 26, 2026 · NCT06802315

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

University of Chicago, Chicago

Ap rekriteFaz 1

Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Northwestern University, Chicago

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT05732103

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Northwestern, Chicago

Ap rekriteFaz 1/2

Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Northwestern Medicine, Chicago

Ap rekriteFaz 1

Laj 12 ak plis · Tout sèks · Mizajou Mar 16, 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Loyola University Medical Center, Maywood

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05735184

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Northshore University Health System, Evanston

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Feb 23, 2026 · NCT05974150

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT06501196

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Northwestern University, Evanston

Ap rekriteVolontè an sante akeyi

Laj 18 a 120 · Tout sèks · Mizajou Jul 25, 2025 · NCT05237258

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.